Michelle Senchyna

Vice President, Clinical Development & Medical Affairs at Aerie Pharmaceuticals, Inc.

Michelle Senchyna

Michelle Senchyna

Vice President, Clinical Development & Medical Affairs at Aerie Pharmaceuticals, Inc.

Biography

Michelle Senchyna is former Director-Clinical Development at PanOptica, Inc. Dr. Senchyna received an undergraduate degree from McMaster University.

Overview
RelSci Relationships

6

Relationships
RelSci Relationships are individuals Michelle Senchyna likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Head-Regulatory Affairs & Project Management at Eyetech Pharmaceuticals, Inc.

Relationship likelihood: Weak

Senior Director of Clinical Development at PanOptica, Inc.

Relationship likelihood: Weak

Chief Medical Officer & Executive Vice President, Research & Development at PanOptica, Inc.

Relationship likelihood: Weak

Executive Director of Clinical Operations at PanOptica, Inc.

Relationship likelihood: Weak

Executive Director of Finance & Controller at PanOptica, Inc.

Relationship likelihood: Weak

President & Chief Executive Officer at PanOptica, Inc.

Relationship likelihood: Weak

Paths to Michelle Senchyna
Potential Connections via
Relationship Science
You
Michelle Senchyna
Vice President, Clinical Development & Medical Affairs at Aerie Pharmaceuticals, Inc.
Education

McMaster University is a public research university located in Hamilton, Ontario, Canada. The main campus is located on 121 hectares (300 acres) of land near the residential neighbourhoods of Ainslie Wood and Westdale, adjacent to Hamilton's Royal Botanical Gardens. McMaster was controlled by the Baptist Convention of Ontario and Quebec until it became a privately chartered, publicly funded non-denominational institution in 1957. The university is co-educational, and has over 25,000 undergraduate and over 4,000 post-graduate students

Career History
Vice President, Clinical Development & Medical Affairs
2020 - Current

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

Director-Clinical Development
Prior

PanOptica, Inc. operates as a biopharmaceutical company that provides ophthalmology drugs for treatment of eye diseases. The company was founded by Paul G. Chaney and Martin B. Wax in March 2009 and is headquartered in Bernardsville, NJ.

Other Affiliations

Michelle Senchyna is affiliated with Aerie Pharmaceuticals, Inc., PanOptica, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michelle Senchyna. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michelle Senchyna's profile does not indicate a business or promotional relationship of any kind between RelSci and Michelle Senchyna.